2C3D

Company Overview

Snapshot

Founded in June 2023 by Or Litman and Lior Saban, 2C3D operates with 1–10 employees. The company has secured $40K across one funding round.

Business overview

2C3D is dedicated to advancing melanoma cancer treatment by integrating advanced diagnostic methods and digital pathology. The company's core technology focuses on achieving complete eradication of melanoma through a single surgical procedure, with the potential to extend these methods to other skin tumors. By studying the functional properties of melanoma, 2C3D aims to enhance treatment outcomes and reshape the landscape of skin cancer treatment, serving the healthcare and life sciences sectors, particularly medical devices and patients.

Company Intelligence Q&A

When was 2C3D founded?

2C3D was founded in June 2023 by co-founders Or Litman and Lior Saban.

What is 2C3D's primary focus?

2C3D is focused on revolutionizing skin tumor resection, specifically advancing melanoma cancer treatment through state-of-the-art diagnostic methods and digital pathology.

How much capital has 2C3D raised?

2C3D has raised $40K across one funding round.

What is 2C3D's approach to melanoma treatment?

2C3D's unique approach aims to achieve complete eradication of melanoma through a singular surgical procedure, by studying the functional properties of melanoma to enhance treatment outcomes.